{"commentary":{"count":14,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":10,"podcast":2,"x_thread":1,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05384587\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ASC2ESCALATE","nct_id":"NCT05384587","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=asc2escalate-nct05384587. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"ASC2ESCALATE","arms":[{"description":"80 mg initial oral dose taken once a day with possible dose escalation","label":"Asciminib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-10-17","type":"ESTIMATED"},"conditions":["Chronic Myelogenous Leukemia - Chronic Phase"],"enrollment":{"count":34,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"asciminib","type":"DRUG"}],"last_update":"2025-10-14","lead_sponsor":"Novartis Pharmaceuticals","official_title":"A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-08-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of participants who achieve Major Molecular Response (MMR) in the 2L setting","timeFrame":"Baseline up to 12 months"}],"references":[{"citation":"Atallah EL, Mauro MJ, Sasaki K, Levy MY, Koller P, Yang D, Laine D, Sabo J, Gu E, Cortes JE. Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial. Future Oncol. 2024;20(38):3065-3075. doi: 10.1080/14796694.2024.2402680. Epub 2024 Oct 10.","pmid":"39387441","type":"DERIVED"}],"start_date":{"date":"2022-11-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","url":"https://clinicaltrials.gov/study/NCT05384587"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/asc2escalate-nct05384587"}